MACROGENICS INC. - COMMON STOCK

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

25 июл 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

08 июл 2022 16:30:00 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conference

08 июн 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Appointment of William Heiden to Board of Directors

23 май 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conference

17 май 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

03 май 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call

25 апр 2022 16:11:56 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

03 мар 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

24 фев 2022 16:01:01 Источник Nasdaq GlobeNewswire

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

14 фев 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

03 фев 2022 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

03 ноя 2021 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results

02 ноя 2021 16:01:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

26 окт 2021 16:30:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

16 сен 2021 02:45:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

16 сен 2021 02:45:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

12 сен 2021 19:00:00 Источник Nasdaq GlobeNewswire

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

07 сен 2021 16:30:00 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

02 сен 2021 16:30:00 Источник Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

05 авг 2021 16:30:00 Источник Nasdaq GlobeNewswire